Degnan Chris 4
4 · UroGen Pharma Ltd. · Filed Oct 9, 2025
Insider Transaction Report
Form 4
Degnan Chris
Chief Financial Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2025-10-08+4,483→ 4,483 total - Sale
Ordinary Shares
2025-10-08$16.85/sh−2,203$37,121→ 2,280 total - Exercise/Conversion
Restricted Stock Units
2025-10-08−4,483→ 8,967 total→ Ordinary Shares (4,483 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
- [F2]Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
- [F3]The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025.